Close Menu

If you remember anyone who used to say that biotech would never amount to anything, now's the time to make the told-you-so phone call. Biogen Idec says it is considering a possible sale of the company, and one of the interested parties is Carl Icahn, who offered at least $23 billion, according to this article in the Wall Street Journal. Biogen Idec has a market cap of about $23.5 billion.

 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.

Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.

Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.

In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.